MorphoSys AG (MOR) PT Set at €76.00 by Commerzbank Ag
A number of other analysts have also recently issued reports on MOR. Berenberg Bank set a €68.00 ($79.07) price objective on shares of MorphoSys AG and gave the stock a buy rating in a research note on Friday, July 14th. HSBC Holdings plc set a €59.00 ($68.60) price objective on shares of MorphoSys AG and gave the stock a neutral rating in a research note on Friday, July 14th. Goldman Sachs Group, Inc. (The) set a €55.00 ($63.95) price objective on shares of MorphoSys AG and gave the stock a neutral rating in a research note on Monday, July 17th. Independent Research GmbH set a €77.00 ($89.53) price objective on shares of MorphoSys AG and gave the stock a buy rating in a research note on Monday, July 17th. Finally, J P Morgan Chase & Co reissued a neutral rating on shares of MorphoSys AG in a research note on Monday, July 17th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of €81.25 ($94.48).
Shares of MorphoSys AG (ETR:MOR) opened at €76.54 ($89.00) on Tuesday. MorphoSys AG has a 52 week low of €38.14 ($44.35) and a 52 week high of €82.13 ($95.50).
TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/11/morphosys-ag-mor-pt-set-at-76-00-by-commerzbank-ag.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.